{
    "ticker": "MRKR",
    "name": "Marker Therapeutics, Inc.",
    "description": "Marker Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative T cell therapies for the treatment of cancer. Founded in 2010 and headquartered in Houston, Texas, Marker is committed to harnessing the power of the immune system to fight cancer. The company specializes in multiTAA T cell therapy, which is designed to target multiple tumor antigens, potentially enhancing the efficacy and durability of treatment while minimizing side effects. Marker\u2019s lead product candidate, MT-401, is being developed for patients with acute myeloid leukemia (AML) and other hematological malignancies. The company is also exploring the application of its T cell therapies in solid tumors. By leveraging groundbreaking research and clinical insights, Marker aims to provide transformative therapies that improve patient outcomes. The company's mission is to bring hope to patients facing the challenges of cancer through the advancement of personalized medicine and targeted immunotherapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Houston, Texas, USA",
    "founded": "2010",
    "website": "https://www.markertherapeutics.com",
    "ceo": "Peter L. Hoang",
    "social_media": {
        "twitter": "https://twitter.com/MarkerTx",
        "linkedin": "https://www.linkedin.com/company/marker-therapeutics"
    },
    "investor_relations": "https://ir.markertherapeutics.com",
    "key_executives": [
        {
            "name": "Peter L. Hoang",
            "position": "CEO"
        },
        {
            "name": "Kathy W. H. Lee",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "T Cell Therapies",
            "products": [
                "MT-401"
            ]
        }
    ],
    "seo": {
        "meta_title": "Marker Therapeutics, Inc. | Innovative T Cell Therapies for Cancer",
        "meta_description": "Discover Marker Therapeutics, Inc., a leader in developing innovative T cell therapies aimed at treating cancer. Learn about our commitment to personalized medicine and patient outcomes.",
        "keywords": [
            "Marker Therapeutics",
            "T Cell Therapy",
            "Cancer Treatment",
            "Immunotherapy",
            "MT-401"
        ]
    },
    "faq": [
        {
            "question": "What does Marker Therapeutics focus on?",
            "answer": "Marker Therapeutics focuses on developing innovative T cell therapies for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Marker Therapeutics?",
            "answer": "Peter L. Hoang is the CEO of Marker Therapeutics, Inc."
        },
        {
            "question": "Where is Marker Therapeutics headquartered?",
            "answer": "Marker Therapeutics is headquartered in Houston, Texas, USA."
        },
        {
            "question": "What is Marker Therapeutics' lead product candidate?",
            "answer": "Marker Therapeutics' lead product candidate is MT-401, developed for patients with acute myeloid leukemia and other hematological malignancies."
        },
        {
            "question": "When was Marker Therapeutics founded?",
            "answer": "Marker Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "BLUE",
        "KITE",
        "CRSP",
        "ZIOP"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "MRNA",
        "NVTA"
    ]
}